Concepts (121)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 11 | 2017 | 43 | 1.910 |
Why?
|
| Triazoles | 5 | 2015 | 29 | 1.440 |
Why?
|
| Mycoses | 4 | 2017 | 23 | 1.270 |
Why?
|
| Blastomycosis | 6 | 2012 | 21 | 1.000 |
Why?
|
| Lung Diseases, Fungal | 2 | 2017 | 10 | 0.650 |
Why?
|
| Histoplasmosis | 2 | 2017 | 8 | 0.650 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 15 | 0.560 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 16 | 0.560 |
Why?
|
| Neuroaspergillosis | 1 | 2015 | 2 | 0.480 |
Why?
|
| Brain Abscess | 1 | 2015 | 5 | 0.480 |
Why?
|
| Coccidioidomycosis | 3 | 2015 | 7 | 0.430 |
Why?
|
| Blastomyces | 2 | 2010 | 10 | 0.410 |
Why?
|
| Meningitis, Fungal | 2 | 2015 | 2 | 0.360 |
Why?
|
| Pyomyositis | 1 | 2009 | 5 | 0.320 |
Why?
|
| Extremities | 1 | 2009 | 28 | 0.320 |
Why?
|
| Pyrimidines | 2 | 2009 | 22 | 0.310 |
Why?
|
| Anus Diseases | 1 | 2008 | 2 | 0.300 |
Why?
|
| Ulcer | 1 | 2008 | 7 | 0.300 |
Why?
|
| Peptides, Cyclic | 2 | 2004 | 10 | 0.280 |
Why?
|
| Mouth Diseases | 1 | 2006 | 3 | 0.270 |
Why?
|
| Peptides | 2 | 2004 | 103 | 0.260 |
Why?
|
| Male | 12 | 2017 | 15289 | 0.230 |
Why?
|
| Ascomycota | 1 | 2004 | 2 | 0.230 |
Why?
|
| Mitosporic Fungi | 1 | 2004 | 3 | 0.230 |
Why?
|
| Adult | 12 | 2017 | 8104 | 0.230 |
Why?
|
| Fungemia | 1 | 2004 | 8 | 0.230 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2004 | 23 | 0.230 |
Why?
|
| Aspergillosis | 2 | 2017 | 11 | 0.230 |
Why?
|
| Trichosporon | 1 | 2003 | 2 | 0.220 |
Why?
|
| Peritonitis | 1 | 2003 | 17 | 0.220 |
Why?
|
| Humans | 20 | 2017 | 28431 | 0.220 |
Why?
|
| Renal Dialysis | 1 | 2004 | 123 | 0.210 |
Why?
|
| Aspergillus | 2 | 2017 | 7 | 0.200 |
Why?
|
| Voriconazole | 3 | 2015 | 12 | 0.200 |
Why?
|
| Female | 12 | 2017 | 15725 | 0.180 |
Why?
|
| Middle Aged | 10 | 2017 | 9268 | 0.180 |
Why?
|
| Aged | 8 | 2017 | 9277 | 0.160 |
Why?
|
| Histoplasma | 1 | 2017 | 4 | 0.140 |
Why?
|
| Endemic Diseases | 1 | 2017 | 7 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2015 | 3615 | 0.140 |
Why?
|
| Melioidosis | 1 | 2015 | 3 | 0.130 |
Why?
|
| Burkholderia pseudomallei | 1 | 2015 | 3 | 0.130 |
Why?
|
| Antigens, Fungal | 1 | 2015 | 1 | 0.130 |
Why?
|
| Travel | 1 | 2015 | 14 | 0.130 |
Why?
|
| Tablets | 1 | 2015 | 6 | 0.120 |
Why?
|
| Central Nervous System | 1 | 2015 | 59 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 28 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2017 | 3612 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2017 | 1926 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 383 | 0.100 |
Why?
|
| Itraconazole | 1 | 2012 | 4 | 0.100 |
Why?
|
| HIV Infections | 2 | 2010 | 488 | 0.100 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 2 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 8 | 0.090 |
Why?
|
| Antigen Presentation | 1 | 2010 | 13 | 0.090 |
Why?
|
| Radiography | 2 | 2010 | 640 | 0.090 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2010 | 2 | 0.090 |
Why?
|
| Aspergillus flavus | 1 | 2009 | 3 | 0.080 |
Why?
|
| Mediastinitis | 1 | 2009 | 6 | 0.080 |
Why?
|
| Mediastinum | 1 | 2009 | 7 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 31 | 0.080 |
Why?
|
| Quadriceps Muscle | 1 | 2009 | 32 | 0.080 |
Why?
|
| Adolescent | 4 | 2010 | 2307 | 0.080 |
Why?
|
| HIV-1 | 1 | 2010 | 236 | 0.070 |
Why?
|
| Sexuality | 1 | 2008 | 15 | 0.070 |
Why?
|
| Echinocandins | 2 | 2004 | 6 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 1143 | 0.070 |
Why?
|
| Lipopeptides | 2 | 2004 | 10 | 0.070 |
Why?
|
| Alternaria | 1 | 2006 | 1 | 0.070 |
Why?
|
| Deoxycholic Acid | 1 | 2006 | 2 | 0.070 |
Why?
|
| Amphotericin B | 1 | 2006 | 6 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2006 | 36 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 397 | 0.060 |
Why?
|
| Brain | 1 | 2015 | 1663 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2006 | 441 | 0.060 |
Why?
|
| Candida | 1 | 2004 | 12 | 0.060 |
Why?
|
| Laboratories | 1 | 2004 | 10 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2004 | 87 | 0.060 |
Why?
|
| Prospective Studies | 1 | 2009 | 1809 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 730 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 62 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2002 | 141 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 117 | 0.030 |
Why?
|
| United States | 2 | 2015 | 2200 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 18 | 0.030 |
Why?
|
| Coccidioides | 1 | 2015 | 2 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 48 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 40 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 46 | 0.030 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 4 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 17 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 13 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 11 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 9 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 74 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 73 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 59 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 84 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2010 | 58 | 0.020 |
Why?
|
| Tomography | 1 | 2010 | 13 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 221 | 0.020 |
Why?
|
| Head | 1 | 2010 | 22 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 30 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2009 | 22 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 284 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 396 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 283 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 113 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 220 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 372 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 717 | 0.020 |
Why?
|
| Illinois | 1 | 2005 | 246 | 0.010 |
Why?
|
| Fluconazole | 1 | 2004 | 9 | 0.010 |
Why?
|
| Geography | 1 | 2004 | 18 | 0.010 |
Why?
|
| Quality Control | 1 | 2004 | 32 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2069 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 688 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 737 | 0.010 |
Why?
|
| Child | 1 | 2005 | 1420 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2002 | 677 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 4857 | 0.010 |
Why?
|